Vectura Group (Chippenham, UK) is acquiring fellow Skyepharma (London, UK) in a deal worth $441 million. The move brings together the two companies' complementary inhaled formulation, development regulatory and device expertise to accelerate growth in the inhaled respiratory market.
Roche enters a collaboration agreement with Blueprint Medicines (Cambridge, MA, USA) to research, develop and market small molecule kinase-targeting immunotherapy drugs for as many as five cancer targets in a deal valued at more than $1 billion. Most cancer immunotherapies, including Roche’s development candidates, have focused on antibodies or combinations with existing approved therapies and have not yet targeted immunokinases with small molecules. Under the terms of the deal, Roche will pay $45 million upfront and $965 million in milestone and contingent milestones and get exclusively license drugs arising from the partnership.
Sanofi and DiCE Molecules (San Francisco, CA, USA) enter into a five-year collaboration to discover new therapeutics for up to twelve novel targets in areas of interest including oncology, cardiovascular and diabetes. The plan consists in leveraging DiCE’s technology platform to address difficult chemistry issues and enable monoclonal antibodies to be replaced by orally administered medicines. The collaboration falls under Sanofi's Sunrise Initiative, a strategic partnership model that invests in early stage transformative opportunities. Sanofi will fund up to $50 million in equity and upfront and make payment of up to $184 million for each compound developed.
GlaxoSmithKline enters a strategic collaboration with Miltenyi Biotech (Bergish Gladbach, Germany) to optimize the manufacture and delivery of cell and gene therapies in oncology and rare diseases. Under the alliance, Miltenyi Biotec will integrate greater automation and high-tech processing technology into GSK’s current manufacturing capabilities. The collaboration also aims at advancing the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics. Financial terms of the deal were not disclosed.
….and stops a five-year collaboration with Five Prime Therapeutics (South San Francisco, CA, USA) for the development of FP-1039 as a treatment for mesothelioma cancer a few months after GSK has stopped the development of the drug for squamous non-small cell lung cancer.
Johnson & Johnson Innovation launches JLINX, a new biotechnology incubator, located on the Janssen campus in Bersee (Belgium) which will be managed through a close collaboration with bioqube ventures. J&J companies will not hold any specific rights to commercialised products by virtue of the JLINX relationship.
Takeda Pharmaceutical teams up with Frazier Healthcare Partners (Menlo Park, CA, USA), to launch Outpost Medicine a new startup company that will specialize in the development of novel treatments for urological diseases. Outpost Medicine has received $41 million in funding and acquired the global rights to a clinical-stage oral drug from Takeda, renamed OP-233, which it will develop for the treatment of stress urinary incontinence
Nanobiotix (Paris, France) has made a private placement of about $23.6 million to fund the clinical trials of its NBTXR3, a nanoparticle drug along with radiotherapy, including combination therapies with immune-oncology treatments.
Approval of drugs, vaccines, diagnostics and devices
US FDA approves Bayer’s Kovaltry, (octocog alfa; BAY 81-8973) an unmodified full-length recombinant factor VIII product for the treatment of children and adults with hemophilia A. Kovaltry was approved in Europe and in Canada last month.
US FDA extends Pfizer’s Xalkori or crizotinib, a kinase inhibitor, as a treatment for advanced or metastatic non-small cell lung cancer patients with ROS1 gene mutation. Xalkori was previously approved as a treatment against ALK-positive non-small cell lung cancer.
Drugs at clinical stage
US FDA grants fast-track status to Omeros’ (Seattle, WA, USA) OMS721, a monoclonal antibody, as a subcutaneous treatment for patients with atypical hemolytic uremic syndrome.
US FDA grants orphan status to DelMar’s (Vancouver, Canada and Menlo Park, CA, USA) VAL-083, or dianhydrogalactilol, for medulloblastoma, a tumor located in the lower rear portion of the brain. The drug already had orphan status as a treatment of glioma.
US FDA grants Roche’s atezolizumab priority review status as a treatment for patients with locally advanced or metastatic urothelial carcinoma.
CymaBay’s (Newark, CA, USA) MBX-8025, a PPARδ agonist, shows positive results in a Pilot Phase 2 study in patients with homozygous familial hypercholesterolemia cholesterol study but with unexpected elevation in PCSK9.
GW Pharmaceuticals’ (London, UK) Epidiolex, or cannabidiol, meets a major clinical primary endpoint in the treatment of Dravet syndrome, a rare and very difficult to treat form of childhood epilepsy, for which there are currently no approved therapies.Epidiolex has been awarded both Orphan Drug Designation and Fast Track Designation by the US.
Science and Technology
The International Olympic Committee (IOC) has selected GE Healthcare's Centricity Practice Solution to handle the health services of all of the athletes, as well as their families, coaches, the officials and even spectators.
Medical Devices and Diagnosis News
US FDA advisory panel of experts voted 9-0 to recommend approval of Abbott’s Absorb, the first bioresorbable stent, based on an analysis of its risks and rewards. Absorb achieved a CE mark in 2010, and is used widely in several countries including India and Brazil.
Abbott's Absorb bioresorbable stent–Courtesy of Abbott
GlaxoSmithKline is making efforts to roll out miniaturized implantable bioelectronics devices on peripheral nerves that send electric pulses to treat chronic diseases such as obesity, hypertension or diabetes.
Cost, Pricing and Market Access
The UK National Institute for Health and Care Excellence (NICE) turns down Amgen’s Imlygic, also known as T-Vec (talimogene laherparepvec), a modified form of the herpes simplex virus type-1 which was approved in Europe as the first oncolytic immunotherapy to treat adults with unresectable melanoma. Carole Longson, director of the Centre for Health Technology Evaluation at NICE, noted that Imlygic represents an innovative approach to treating the disease, “However, the committee concluded that there was not enough evidence to be able to say whether Imlygic is as clinically effective as other drugs used to treat advanced melanoma. Given the uncertainty about its effect on overall survival compared with these drugs it was not possible to recommend Imlygic as a cost-effective use of NHS resources.”
In a rare move Welsh government overrules NICE rejection of Celgene’s Abraxane (nab-paclitaxel) as a treatment for pancreatic cancer and ensures continued access, in Wales, to the drug in combination with gemcitabine.
110 French oncologists and hematologists sign a common declaration in Le Figaro, a daily French newspaper, to protest against “unjustified” excessive prices of newly approved cancer drugs.
The European Medicines Agency is undertaking a safety review of Gilead’s cancer drug Zydelig, or idelalisib, because three ongoing clinical trials, investigating the drug in combination with other cancer medicines, have shown an increased rate of serious side effects including deaths, mostly due to infections. The drug is currently approved in the EU to treat two rare blood cancers chronic lymphocytic leukaemia (CLL) and follicular lymphoma.
Praluent Patent Litigation. Sanofi and Regeneron Pharmaceuticals announced today that the companies strongly disagree with a US District Court jury verdict that the asserted claims of two Amgen patents for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are valid. Sanofi and Regeneron believe these Amgen patent claims are invalid in the ongoing US patent infringement lawsuit and plan to appeal the judgment.
GlaxoSmithKline has announced that its chief executive officer Sir Andrew Witty is to retire in March next year.
The UK House of Commons has officially launched the All-Party Parliamentary Group of Personalised Medicine to help the National Health Service and patients make best use of the increasing availability of new technologies to provide more personalised health and care.
The 2016 Paul Ehrlich and Ludwig Darmstaedter Prize is awarded to Emmanuelle Charpentier from France and Jennifer A. Doudna from the USA for their pioneering work in the development of the programmable gene editing tool CRISPR-Cas9 technology (see newsweek 2015 #52-53). The Prize is traditionally awarded on Paul Ehrlich's birthday, March 14, in the Paulskirche, Frankfurt (Germany). It honors scientists who have made significant contributions in Paul Ehrlich's field of research, in particular immunology, cancer research, microbiology, and chemotherapy.
- BioPharma Asia Convention on March 22-24 in Singapore (Singapore)
- Annual China Healthcare Investment Conference on March 29-31 in Shanghai (China)
- BIO Europe Spring on April 4-6 in Stockholm (Sweden)
- BIO-IT World Conference & Expo’16 on April 5-7 in Boston (USA)
- BIO Vision on April 13-14 in Lyon (France)
- BIO Trinity on April 25-27 in London (UK)
- Bio€quity Europe 2016 on May 10-11 in Copenhagen (Denmark)
- Strategic Alliance Management Congress on May 16-18 in Philadelphia (USA)
- China BIO Partnering Forum on May 18-19 in Suzhou (China)
- BIO International Convention on June 6-9 in San Francisco (USA)
- BIO Pharm America on September 13-15 in Boston (USA)
- 7th Innovation Days on October 3-4 in Paris (France)
- BIO Europe on November 7-9 in Cologne (Germany)
- BIO Latam on November 29-30 in San Juan (Puerto Rico)
- Biofit 2016 on November 30-December 1 in Lille (France)
IMPORTANT NOTICE: This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Author: Jean-Claude Muller, 穆卓Special Advisor at I&IR and Executive Editor at BtoBioInnovation, jcm@
Give us your feed-back on the biopharmaceutical News !
Discover our services in Marketing & Business Development:
See All News